Jim Cramer Recently Answered Questions About These 10 Stocks

6. GRAIL, Inc. (NASDAQ:GRAL)

Number of Hedge Fund Holders: 28

GRAIL, Inc. (NASDAQ:GRAL) is one of the stocks Jim Cramer recently answered questions about. Responding to a caller’s question about the stock during the lightning round, Cramer remarked:

“Yeah, and I just read a really good piece the other day written by Dr. Topol, who’s been on the show a number of times. It did not make me feel that it was worth a, you know, I just didn’t think it was worth owning after this very big parabolic move. I’m going to say absolutely not to that one.”

GRAIL, Inc. (NASDAQ:GRAL) develops and markets blood-based tests for early cancer detection, including its Galleri screening test for multiple cancers. On October 17, it announced positive results from its PATHFINDER 2 study of the Galleri multi-cancer early detection test. The study included 35,878 adults, and it showed that adding Galleri to standard screenings increased cancer detection more than seven-fold, with over half of the detected cases found at early stages, and about three-quarters of the cancers detected by Galleri lack existing screening options.

In addition, Galleri demonstrated 99.6% specificity, a 0.4% false positive rate, and correctly identified the cancer’s origin 92% of the time. There were no serious study-related adverse events, and GRAIL, Inc. (NASDAQ:GRAL) is planning to submit the data to the FDA for premarket approval in the first half of 2026.